Literature DB >> 32475799

A case of COVID-19 with long duration of viral shedding.

Changtai Wang1, Mengyuan Xu2, Zhenhua Zhang3.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32475799      PMCID: PMC7245199          DOI: 10.1016/j.jmii.2020.05.008

Source DB:  PubMed          Journal:  J Microbiol Immunol Infect        ISSN: 1684-1182            Impact factor:   4.399


× No keyword cloud information.
Dear Editor, Coronavirus disease-19 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has become a major threat to global health.1, 2, 3 The median range of viral shedding has been reported to be 11–20 days, with 49 days being the longest viral shedding period ever reported. , In this report, however, we describe a special case of COVID-19 in which, despite the presence of SARS-CoV-2 antibodies, SARS-CoV-2 RNA has so far persisted in throat/nasal swab for over 72 days after disease onset. On January 29, 2020, a 59-year-old woman with a history of hypertension and diabetes was diagnosed of COVID-19 by a COVID-19 special temporary hospital in Wuhan. She manifested intermittent fever and dry cough. Her highest body temperature was 38.0 °C. Lung CT showed scattered ground glass-like opacities in bilateral lungs on day 2 and 10. Her temperature dropped to normal levels within 2 days and her coughing disappeared within 5 days. SARS-CoV 2 RNA tested positive on a throat swab sample by real-time reverse-transcription PCR (RT-PCR) on day 12 from disease onset (February 9, 2020). Even though the patient has been symptom free since the first week of her first hospital stay, she has been isolated continuously in home, hotel or hospitals, and has been treated with antibiotics and traditional Chinese medicine (TCM) due to intermittent positive SARS-CoV-2 RNA test results. In fact, she tested positive for SARS-CoV-2 RNA on specimens collected from throat or nasal swabs on days 12, 23, 31, 53, 64, 66, and 72 but negative on days 21, 29, 35, 37, 50, 61, 68, 70 (Table 1 ). Notably, SARS-CoV-2 IgM and IgG antibody showed positive (65.33 and 207.84 AU/ml, respectively, <10 AU/ml indicate negative) on 38 days from disease onset (March 6. 2020).
Table 1

Clinical course, laboratory findings, and treatment of the case of COVID-19.

Note: a, Hot-1,2 is for different hotels; b, Hos-1,2,3 is for different hospitals; c, Red is positive and green is negative; d, TCM-1,2,3 is for different traditional Chinese medicine.

Clinical course, laboratory findings, and treatment of the case of COVID-19. Note: a, Hot-1,2 is for different hotels; b, Hos-1,2,3 is for different hospitals; c, Red is positive and green is negative; d, TCM-1,2,3 is for different traditional Chinese medicine. Follow-up lung CT scans showed that, on day 31 after onset, the patchy infiltration of both lungs was significantly reduced, and almost disappeared on day 54 (only 1.8% of the lung tissues were involved). During the course of the disease, the patient's blood routines, liver and kidney functions were normal, blood pressure remained stable and the blood glucose slightly increased temporarily. The case we are reporting suggests that SARS-CoV-2 virus can coexist with patients for a long time, and chronic infection can not be ruled out. Given that SARS-CoV-2 is very contagious, if the SARS-CoV-2 infection can last for several months or even become chronic in the patient's body, it would be extremely difficult to quarantine the patient for a long period of time, which would be disastrous for the global control of SARS-CoV-2 infection. Therefore, for discharged COVID-19 patients, continuous detection of SARS-CoV-2 RNA is required. It is widely accepted that high affinity IgG response is important for long term immunity and immunological memory. In the patient, IgM and IgG antibody against SARS-CoV-2 were positive on 38 days from disease onset, unfortunately the patient was subsequently detected to carry the virus.

Funding

This study was funded by the (Grant no. 1608085MH162).

Declaration of Competing Interest

The authors have no conflict of interest to be declared.
  3 in total

1.  Development and clinical application of a rapid IgM-IgG combined antibody test for SARS-CoV-2 infection diagnosis.

Authors:  Zhengtu Li; Yongxiang Yi; Xiaomei Luo; Nian Xiong; Yang Liu; Shaoqiang Li; Ruilin Sun; Yanqun Wang; Bicheng Hu; Wei Chen; Yongchen Zhang; Jing Wang; Baofu Huang; Ye Lin; Jiasheng Yang; Wensheng Cai; Xuefeng Wang; Jing Cheng; Zhiqiang Chen; Kangjun Sun; Weimin Pan; Zhifei Zhan; Liyan Chen; Feng Ye
Journal:  J Med Virol       Date:  2020-04-13       Impact factor: 2.327

Review 2.  Asymptomatic carrier state, acute respiratory disease, and pneumonia due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): Facts and myths.

Authors:  Chih-Cheng Lai; Yen Hung Liu; Cheng-Yi Wang; Ya-Hui Wang; Shun-Chung Hsueh; Muh-Yen Yen; Wen-Chien Ko; Po-Ren Hsueh
Journal:  J Microbiol Immunol Infect       Date:  2020-03-04       Impact factor: 4.399

3.  Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study.

Authors:  Fei Zhou; Ting Yu; Ronghui Du; Guohui Fan; Ying Liu; Zhibo Liu; Jie Xiang; Yeming Wang; Bin Song; Xiaoying Gu; Lulu Guan; Yuan Wei; Hui Li; Xudong Wu; Jiuyang Xu; Shengjin Tu; Yi Zhang; Hua Chen; Bin Cao
Journal:  Lancet       Date:  2020-03-11       Impact factor: 79.321

  3 in total
  5 in total

Review 1.  Various theranostics and immunization strategies based on nanotechnology against Covid-19 pandemic: An interdisciplinary view.

Authors:  Sujan Chatterjee; Snehasis Mishra; Kaustav Dutta Chowdhury; Chandan Kumar Ghosh; Krishna Das Saha
Journal:  Life Sci       Date:  2021-05-12       Impact factor: 6.780

2.  SARS-CoV-2 RNA Persistence in Naso-Pharyngeal Swabs.

Authors:  Maria Luisa Danzetta; Laura Amato; Francesca Cito; Alessandra Di Giuseppe; Daniela Morelli; Giovanni Savini; Maria Teresa Mercante; Alessio Lorusso; Ottavio Portanti; Ilaria Puglia; Federica Monaco; Claudia Casaccia; Annapia Di Gennaro; Lilia Testa; Giacomo Migliorati; Nicola D'Alterio; Paolo Calistri
Journal:  Microorganisms       Date:  2020-07-26

3.  Results of an early second PCR test performed on SARS-CoV-2 positive patients may support risk assessment for severe COVID-19.

Authors:  Barak Mizrahi; Maytal Bivas-Benita; Nir Kalkstein; Pinchas Akiva; Chen Yanover; Yoav Yehezkelli; Yoav Kessler; Sharon Hermoni Alon; Eitan Rubin; Gabriel Chodick
Journal:  Sci Rep       Date:  2021-10-14       Impact factor: 4.379

Review 4.  Laboratory diagnosis of COVID-19 in China: A review of challenging cases and analysis.

Authors:  Ran Jing; Timothy Kudinha; Meng-Lan Zhou; Meng Xiao; He Wang; Wen-Hang Yang; Ying-Chun Xu; Po-Ren Hsueh
Journal:  J Microbiol Immunol Infect       Date:  2020-10-17       Impact factor: 4.399

5.  Case of Prolonged Viral Shedding: Chronic, Intermittan COVID-19?

Authors:  Bilkay Serez Kaya; İlker Yılmam; Ebru Çakır Edis; Derya Karabulut; Tülin Elmaslar Mert; Canan Eryıldız; Muzaffer Demir
Journal:  Turk Thorac J       Date:  2022-01
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.